Steven Romano - Mallinckrodt Plc President

MNKDelisted Stock  USD 0.46  0.02  4.17%   

President

Dr. Steven Romano is Executive Vice President and Chief Scientific Officer of the Company. He joined Mallinckrodt in May 2015 and has executive responsibility for research and development, medical affairs and regulatory affairs functions since 2016.
Age 59
Tenure 8 years
Professional MarksPh.D
Phone353 1 696 0000
Webhttps://www.mallinckrodt.com
Romano is a boardcertified psychiatrist with more than 20 years of experience in the pharmaceutical industry. Previously, Dr. Romano spent 16 years at Pfizer, Inc. where he held a series of senior medical and R&D roles of increasing responsibility, culminating with his role as Senior Vice President, Head, Global Medicines Development, Global Innovative Pharmaceuticals Business. Prior to joining Pfizer, he spent four years at Eli Lilly & Co. After receiving his A.B. in Biology from Washington University in St. Louis and his medical degree from the University of MissouriColumbia, Dr. Romano completed his residency and fellowship at New York HospitalCornell Medical Center, continuing on the faculty of the medical school for six additional years.

Mallinckrodt Plc Management Efficiency

Mallinckrodt Plc's management efficiency ratios could be used to measure how well Mallinckrodt Plc manages its routine affairs as well as how well it operates its assets and liabilities.
Mallinckrodt Plc has 3.07 B in debt with debt to equity (D/E) ratio of 1.44, which is OK given its current industry classification. Mallinckrodt Plc has a current ratio of 2.92, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Mallinckrodt to invest in growth at high rates of return.

Similar Executives

Found 14 records

PRESIDENT Age

Darren KarasiukAurora Cannabis
N/A
Carey SquiresAurora Cannabis
N/A
Andre JeromeAurora Cannabis
N/A
Parker JavidLifecore Biomedical
55
Steve DoblerAurora Cannabis
54
Marcie KiziakSNDL Inc
44
Navroop SandhawaliaSNDL Inc
Mike LeeCanopy Growth Corp
47
Rade KovacevicCanopy Growth Corp
33
Dave PatersonCanopy Growth Corp
N/A
Taranvir VanderSNDL Inc
46
Jeffrey JacobsonCronos Group
38
MD MBAShuttle Pharmaceuticals
55
Tyler RobsonSNDL Inc
35
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The company was founded in 1867 and is based in Dublin, Ireland. Mallinckrodt Plc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. It employs 2778 people. Mallinckrodt Plc (MNK) is traded on NYSE MKT Exchange in USA and employs 2,673 people.

Management Performance

Mallinckrodt Plc Leadership Team

Elected by the shareholders, the Mallinckrodt Plc's board of directors comprises two types of representatives: Mallinckrodt Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mallinckrodt. The board's role is to monitor Mallinckrodt Plc's management team and ensure that shareholders' interests are well served. Mallinckrodt Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mallinckrodt Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Global Officer
David Norton, Independent Director
Hugh ONeill, Executive Vice President and President, Autoimmune and Rare Diseases
Steven Romano, Executive Vice President and Chief Scientific Officer
Sigurdur Olafsson, Pres CEO
Mark Trudeau, CEO and President Director and Member of Portfolio Committee
Kneeland Youngblood, Independent Director
Bryan Reasons, Chief Financial Officer, Executive Vice President
Mark Casey, Executive Vice President and Chief Legal Officer
JoAnn Reed, Independent Director
J Carroll, Independent Director
Lisa French, Ex Officer
Kassie Harrold, Ex Officer
Jason Goodson, Exec Devel
Ian Watkins, Chief Human Resource Officer, Executive Vice President
Stephen Welch, Ex Generics
Henriette Nielsen, Ex Officer
Steven MD, Ex Officer
Angus Russell, Independent Non-Executive Chairman of the Board
Paul Carter, Independent Director
Carlos Paya, Independent Director
Anne Whitaker, Independent Director
Mark Tyndall, Chief VP

Mallinckrodt Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mallinckrodt Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Other Consideration for investing in Mallinckrodt Stock

If you are still planning to invest in Mallinckrodt Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mallinckrodt Plc's history and understand the potential risks before investing.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities